Related references
Note: Only part of the references are listed.Aptamers Overview: Selection, Features and Applications
Luiza I. Hernandez et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2015)
Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors
Dongxi Xiang et al.
THERANOSTICS (2015)
Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells
Walhan Alshaer et al.
BIOCONJUGATE CHEMISTRY (2015)
DNA Aptamers against Exon v10 of CD44 Inhibit Breast Cancer Cell Migration
Joji Iida et al.
PLOS ONE (2014)
Selection of DNA Aptamers against Epithelial Cell Adhesion Molecule for Cancer Cell Imaging and Circulating Tumor Cell Capture
Yanling Song et al.
ANALYTICAL CHEMISTRY (2013)
EpCAM: Structure and function in health and disease
Ulrike Schnell et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2013)
RNA aptamers targeting cancer stem cell marker CD133
Sarah Shigdar et al.
CANCER LETTERS (2013)
In Vitro Selection of Modified RNA Aptamers Against CD44 Cancer Stem Cell Marker
Nidaa Ababneh et al.
NUCLEIC ACID THERAPEUTICS (2013)
Cancer stem cells and their potential implications for the treatment of solid tumors
B. A. Grotenhuis et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Aptamers and Their Biological Applications
Kyung-Mi Song et al.
SENSORS (2012)
EpCAM and its potential role in tumor-initiating cells
Sannia Imrich et al.
CELL ADHESION & MIGRATION (2012)
RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule
Sarah Shigdar et al.
CANCER SCIENCE (2011)
The cancer stem cell: premises, promises and challenges
Hans Clevers
NATURE MEDICINE (2011)
Cancer Stem Cells: Characteristics and Their Potential Role for New Therapeutic Strategies
Stephan R. Bohl et al.
ONKOLOGIE (2011)
Combinatorial Selection of DNA Thioaptamers Targeted to the HA Binding Domain of Human CD44
Anoma Somasunderam et al.
BIOCHEMISTRY (2010)
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies
Markus Muenz et al.
CANCER CELL INTERNATIONAL (2010)
Catumaxomab Clinical development and future directions
Rolf Linke et al.
MABS (2010)
Aptamers as therapeutics
Anthony D. Keefe et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
The Emerging Role of EpCAM in Cancer and Stem Cell Signaling
Markus Munz et al.
CANCER RESEARCH (2009)
Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy
Stefania Bellone et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Nuclear signalling by tumour-associated antigen EpCAM
Dorothea Maetzel et al.
NATURE CELL BIOLOGY (2009)
SELEX-A (r)evolutionary method to generate high-affinity nucleic acid ligands
Regina Stoltenburg et al.
BIOMOLECULAR ENGINEERING (2007)
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer
Gilbert Spizzo et al.
GYNECOLOGIC ONCOLOGY (2006)
Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers
P Went et al.
BRITISH JOURNAL OF CANCER (2006)
2 '-deoxy purine, 2 '-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics
Paula E. Burmeister et al.
OLIGONUCLEOTIDES (2006)
EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy
WA Osta et al.
CANCER RESEARCH (2004)
Share Paper
